Crossmark Global Holdings Inc. Has $984,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Crossmark Global Holdings Inc. decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 16.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,995 shares of the medical research company’s stock after selling 973 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Charles River Laboratories International were worth $984,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Oregon Public Employees Retirement Fund lifted its position in Charles River Laboratories International by 1.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after purchasing an additional 45 shares during the period. American Trust lifted its holdings in shares of Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after acquiring an additional 54 shares during the period. Tortoise Investment Management LLC boosted its position in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares in the last quarter. OLD National Bancorp IN increased its stake in Charles River Laboratories International by 3.1% in the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after acquiring an additional 59 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC lifted its stake in Charles River Laboratories International by 2.0% during the second quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company’s stock worth $652,000 after purchasing an additional 62 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $196.97 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The company’s 50-day moving average is $195.26 and its two-hundred day moving average is $207.82. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The company has a market cap of $10.07 billion, a PE ratio of 24.65, a PEG ratio of 5.57 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $2.72 earnings per share. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has approved a stock buyback plan on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CRL shares. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Redburn Atlantic initiated coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. UBS Group boosted their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, September 20th. Finally, CLSA upgraded shares of Charles River Laboratories International from an “underperform” rating to a “hold” rating and set a $205.00 price target on the stock in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $217.54.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).